Enhancing the Immunogenicity and Protective Efficacy of Rotavirus VP8 Protein by Conjugation to Cholera Toxin B Subunit

Background: Rotavirus (RV) is the leading cause of viral gastroenteritis in infants and young children, accounting for nearly 120,000 deaths annually worldwide. Currently licensed live-attenuated oral RV vaccines show reduced efficacy in low- and middle-income countries and high requirement for vaccine storage and transportation. Consequently, there is an urgent need to develop non-replicating RV vaccines. The VP8* protein of RV has been considered a promising antigen candidate for recombinant protein-based vaccines; however, its intrinsic immunogenicity remains suboptimal. This study aimed to enhance VP8* immunogenicity by conjugating it to the cholera toxin B subunit (CTB) using the SpyCatcher/SpyTag bioconjugation system. Methods: A conjugate protein vaccine, termed VP8::CTB, was generated by coupling SpyTag003-appended RV VP8* (VP8-ST) to SpyCatcher003-fused CTB (CTB-SC). The resulting VP8::CTB conjugate was characterized, and its immunogenicity was evaluated in mice by assessing antigen-specific antibody responses and RV-neutralizing activity. Furthermore, the protective efficacy of purified IgG from immunized mice was investigated by performing a passive protection assay in suckling mice. Results: VP8::CTB elicited significantly higher titers of RV-neutralizing antibodies than VP8-ST alone. Notably, purified IgG from VP8::CTB-immunized mice conferred complete protection against RV-induced diarrhea in suckling mice within the passive protection model. Conclusions: Our findings underscore that the VP8::CTB conjugate, through enhanced immunogenicity and protective efficacy, provides a promising candidate for the advancement of next-generation recombinant protein-based RV vaccines.

Authors

Institutions

Publication Details

Journal
Vaccines
Published
2026-11-19
DOI
https://doi.org/10.3390/vaccines14111000
Primary Topic
Viral gastroenteritis research and epidemiology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Enhancing the Immunogenicity and Protective Efficacy of Rotavirus VP8 Protein by Conjugation to Cholera Toxin B Subunit

Zhong Wei Huang, Yannan Yin, Zhuang Wang, Ziyao Li et al.
Vaccines
Viral gastroenteritis research and epidemiology
article

Enhancing the Immunogenicity and Protective Efficacy of Rotavirus VP8 Protein by Conjugation to Cholera Toxin B Subunit

Zhong Wei Huang, Yannan Yin, Zhuang Wang, Ziyao Li, Xiaozhen Liang, Chiyuan Wang, Ning Li, Lu Li, Wennuo Xu, Huichun Shi, Shuxia Wang
article en

Abstract

Background: Rotavirus (RV) is the leading cause of viral gastroenteritis in infants and young children, accounting for nearly 120,000 deaths annually worldwide. Currently licensed live-attenuated oral RV vaccines show reduced efficacy in low- and middle-income countries and high requirement for vaccine storage and transportation. Consequently, there is an urgent need to develop non-replicating RV vaccines. The VP8* protein of RV has been considered a promising antigen candidate for recombinant protein-based vaccines; however, its intrinsic immunogenicity remains suboptimal. This study aimed to enhance VP8* immunogenicity by conjugating it to the cholera toxin B subunit (CTB) using the SpyCatcher/SpyTag bioconjugation system. Methods: A conjugate protein vaccine, termed VP8::CTB, was generated by coupling SpyTag003-appended RV VP8* (VP8-ST) to SpyCatcher003-fused CTB (CTB-SC). The resulting VP8::CTB conjugate was characterized, and its immunogenicity was evaluated in mice by assessing antigen-specific antibody responses and RV-neutralizing activity. Furthermore, the protective efficacy of purified IgG from immunized mice was investigated by performing a passive protection assay in suckling mice. Results: VP8::CTB elicited significantly higher titers of RV-neutralizing antibodies than VP8-ST alone. Notably, purified IgG from VP8::CTB-immunized mice conferred complete protection against RV-induced diarrhea in suckling mice within the passive protection model. Conclusions: Our findings underscore that the VP8::CTB conjugate, through enhanced immunogenicity and protective efficacy, provides a promising candidate for the advancement of next-generation recombinant protein-based RV vaccines.

VaccinesVol. 14(11)
Shanghai Medical College of Fudan University (CN), East China University of Science and Technology (CN), Fudan University (CN), Shanghai Institute of Materia Medica (CN), Huashan Hospital (CN)
Viral gastroenteritis research and epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon